Table III.
Comparison of blood glucose, body mass index and islet function in two groups respectively prior to and following treatment.
| Group | Blood glucose, mmol/l | HbA1C, % | BMI, kg/m2 | FIns, mU/l | IR index | Pancreatic β cell function | Vascular dilation rates, % | ||
|---|---|---|---|---|---|---|---|---|---|
|
|
|
||||||||
| FBG | 2hPBG | Reactive hyperemia | After nitroglycerin | ||||||
| Metformin (n=47) | |||||||||
| Prior to treatment | 8.0±1.6 | 12.8±3.7 | 7.2±2.4 | 25.6±5.8 | 17.4±5.2 | 7.7±1.6 | 66.6±8.5 | 8.5±2.2 | 15.8±4.3 |
| Following treatment | 6.3±1.6 | 8.9±3.1 | 6.3±2.2 | 22.1±5.5 | 20.2±5.5 | 6.3±1.4 | 112.2±13.7 | 11.3±3.1 | 17.1±4.5 |
| P-value | 0.008 | 0.004 | 0.007 | 0.042 | 0.032 | 0.043 | 0.036 | 0.037 | 0.041 |
| Pioglitazone (n=46) | |||||||||
| Prior to treatment | 8.1±1.6 | 12.7±3.6 | 7.1±2.5 | 25.4±5.7 | 17.2±5.3 | 7.8±1.7 | 68.0±8.8 | 8.7±2.3 | 14.4±4.2 |
| Following treatment | 6.4±1.6 | 9.1±3.2 | 6.4±2.3 | 24.8±5.6 | 19.9±5.3 | 6.1±1.3 | 119.8±14.3 | 9.2±2.4 | 15.7±4.3 |
| P-value | 0.007 | 0.009 | 0.006 | 0.087 | 0.027 | 0.019 | 0.017 | 0.021 | 0.011 |
Values are expressed as mean ± SD. BMI, body mass index; HbA1C, glycosylated hemoglobin; FBG, fasting blood glucose; 2hPBG, 2 h postprandial blood glucose; FIns, fasting insulin; IR, insulin resistance.